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Bone marrow graft failure and poor graft function are frequent complications after hematopoietic stem cell
transplantation and result in signiﬁcant morbidity and mortality. Both conditions are associated with graft-
versus-host disease (GVHD), although the mechanism remains undeﬁned. Here we show, in 2 distinct
murine models of GVHD (complete MHC- and class II-disparate) that mimic human peripheral blood stem cell
transplantation, that Th1 CD4þ cells induce bone marrow failure in allogeneic recipients. Bone marrow failure
after transplantation of allogeneic naïve CD4þ T cells was associated with increased CD4þ Th1 cell devel-
opment within bone marrow and lymphoid tissues. Using IFNg-reporter mice, we found that Th1 cells
generated during GVHD induced bone marrow failure after transfers into secondary recipients. Homing
studies demonstrated that transferred Th1 cells express CXCR4, which was associated with accumulation
within bone marrow and spleen. Allogeneic Th1 cells were activated by radiation-resistant host bone marrow
cells and induced bone marrow failure through an IFNg-dependent mechanism. Thus, allogeneic Th1 CD4þ
cells generated during GVHD trafﬁc to hematopoietic sites and induce bone marrow failure via IFNg-mediated
toxicity. These results have important implications for prevention and treatment of bone marrow graft failure
after hematopoietic stem cell transplantation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Th1 development is under control of the transcription
Hematopoietic stem cell transplantation (HSCT) is an
increasingly utilized therapy for treatment of malignant and
nonmalignant disorders. Although outcomes continue to
improve, signiﬁcant morbidity and mortality continue to
limit this treatment for many patients. Bone marrow (BM)
graft failure and poor graft function occur in up to 25% of
patients undergoing HSCT and both are associated with an
increased risk of infection and death [1,2]. Risk factors for
development of graft failure and poor graft function include
infection, medication side effects, and graft-versus-host
disease (GVHD) [1]. The mechanistic basis for the relation-
ship between GVHD and BM failure remains poorly deﬁned.
Previous adoptive transfer studies have demonstrated
that allogeneic Th17 cells, produced in vitro, induce an
atypical form of GVHDmanifested primarily by skin and lung
disease [3]. Similar studies with Th2 cell transfers indicated
a decreased pathogenicity of these cells in HSCT mouse
models [4,5]. Transfer studies using in vitro-generated Th1
cells have been limited by previous isolation methods, and
no studies have conclusively determined the role of
committed Th1 cells in GVHD using adoptive transfer
methodology [6,7]. Here, using a previously reported IFNg-
reporter mouse model [8], we describe GVHD mediated by
puriﬁed, committed Th1 cells in clinically relevant murine
models.edgments on page 886.
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13.03.007factor, T-bet, which can be upregulated by IL-12 and other
signals [9]. Th1 cells produce the signature cytokine, IFNg,
which acts to further promote Th1 development and
suppress the development of other lineages. T-bet is elevated
in T cells from aplastic anemia patients with BM failure [10].
Previous studies have also demonstrated an important role
for IFNg in BM suppression and failure [11-16]. In addition,
a direct negative effect of IFNg on CD34þ cord blood hema-
topoietic stem cells has been demonstrated [17]. Elegant
studies using IFNg-receptor-deﬁcient recipients revealed
increased levels of IFNg present in recipient blood and
tissues, which was associated with hematopoietic failure and
lymphoid aplasia. Disease in these mice was dependent on
both IFNg and Fas-FasL [18]. IFNg is a ubiquitous cytokine
produced by multiple cell lineages within the immune
system, including Th1 cells. CD8þ cells, in particular, are an
important source of IFNg, and several studies have indicated
that CD8þ cells are critical for inducing BM disease [11,16].
Previous work using polyclonal allogeneic CD4þ cells indi-
cated that IFNg was important for BM disease in the setting
of sublethal conditioning, but not in lethal conditioning [13].
Other studies exploring CD4þ mediated BM suppression
have implicated IFNg-independent mechanisms. Fas-FasL
interactions, in particular, seemed to be important in medi-
ating the BM manifestations in these studies [19,20]. It
remains uncertain, therefore, whether allogeneic Th1 cells
directly mediate suppression of recipient BM function, and, if
so, the mechanism(s) of this suppression.
This study signiﬁcantly extends previous work by deﬁ-
nitely demonstrating that allogeneic Th1 cells directly
mediate host hematopoietic failure. In addition, we haveTransplantation.
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reporter mouse systems, determining allogeneic Th1 cell
homing, and detailed analyses, includingmechanism, of Th1-
mediated suppression of host hematopoiesis.
MATERIAL AND METHODS
Mice
The following mice were purchased from Jackson Laboratory and/or
bred at our facility: BALB/cJ (BALB/c), B6.C-H-2bm12 (bm12), C57BL/6J (B6),
C57BL/6.Ly5.2 (CD45.1-homozygous), B6.MRL-Faslpr/J (Fas deﬁcient), and
B6.129S7-Ifngr1tm1Agt/J (IFNg receptor deﬁcient). The Ifng-reporter BAC-In
transgenic mice were previously described [8]. The 3BBM74 transgenic
TCR mice were a kind gift from E. Palmer (University Hospital, Basel,
Switzerland). All animals were bred and maintained in accordance with the
University of Alabama at Birmingham (UAB) Institutional Animal Care and
Use Committee regulations.
Cell Preparation
CD4þ cells were puriﬁed from pooled spleen and/or lymph nodes by
magnetic bead positive selection (Dynal beads, Invitrogen, Life Technologies,
Grand Island, NY). CD25-depletion was performed using PE-labeled anti-
CD25 antibody (eBiosciences, San Diego, CA) followed by anti-PE magnetic
bead depletion (Miltenyi Biotech, Auburn, CA). Post-sort purity was
conﬁrmed by ﬂow cytometry.
Th1 cell puriﬁcation was performed by ﬁrst isolating lymphocytes from
pooled spleens. Splenocytes were then treated with PE-labeled anti-Thy1.1
(eBiosciences) followed by anti-PE magnetic bead selection (Miltenyi
Biotech).
Donor BM cells were prepared by collecting cells from both femurs and
tibias of donor mice. In all experiments, BM was obtained from CD45.1- or
CD45.2-homozygous donor mice to differentiate from coadministered
donor CD4þ cells. T cell depletion was performed using PE-labeled Thy1.2
antibody (BD Biosciences) followed by anti-PE magnetic bead depletion
(Miltenyi Biotech, San Jose, CA).
Cell Culture
Puriﬁed wild-type B6 CD4þ cells were cultured in vitro with irradiated
B6 splenocytes in Th1 conditions with 1 ng/mL rmIL12 (R&D Systems,
Minneapolis, MN) and 10 mg/mL anti-IL4 antibody (clone 11B11), along with
2.5 mg/mL anti-CD3 (clone 145-11) stimulation. Cells were cultured for 3
days and puriﬁed for transfer.
Transplant Procedure
Donor and recipient mice were 4 to 8 weeks of age at time of trans-
plantation. Transplants were performed according to UAB Institutional
Animal Care and Use Committee-approved protocols. Recipient mice
received 900 cGy of total body irradiation in 2 split fractions 3 hours apart
from an x-irradiator (X-RAD 320, Precision X-ray Inc., North Branford, CT). At
least one hour later, T cell-depleted BM, with or without puriﬁed CD4þ cells,
was administered to anesthetized mice via intravenous injection. Cell doses
and experimental groups speciﬁed in text and legends.
All animals were given water supplemented with Trimethoprim and
Sulfamethoxazole for 4 weeks after transplantation.
Mice were weighed at least twice weekly, and mice exhibiting severe
disease, evidenced by lethargy, severe skin disease, hunching, or weight loss
>20% original weight, were euthanized and scored as dead.
To simplify the manuscript nomenclature, the authors refer to
suppression of BM in the mouse recipients of allogeneic cells as suppression
of recipient bone marrow. However, these recipient mice are lethally irradi-
ated and reconstituted with BM from donor mice.
Flow Cytometric Analysis
Intracellular staining was performed as previously described [21]. Live
cells were identiﬁed using LIVE/DEAD Fixable Far Red Dead Cell Stain
(Invitrogen). All ﬂuorescent antibodies for analysis purchased from eBio-
sciences, unless otherwise speciﬁed. Data were acquired on an LSRII ﬂow
cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star,
Ashland, OR).
Bone Marrow Progenitor Analysis
Red blood cells were lysed using ammonium chloride, and BM cells were
stained for 30 minutes in HBSS, 2% FBS containing the following antibody
combinations. Both stains included anti-c-Kit (2B8; BD Pharmingen) and
Sca-1 (E13-161.7; Biolegend, San Diego, CA) antibodies conjugated to APC
and Paciﬁc Blue, respectively, and, for the lineage stains, PE-Cy7 conjugated
antibodies against CD3 (145-2C11), CD4 (RM4-5), CD8 (53-6.7), B220 (RA3-
6B2), CD19 (1D3), Mac-1 (M1/70), Gr-1 (RB6-8C5), and TER119 (TER119). PE-conjugated anti-IL7-Ra (SB/199: BD Pharmingen) was included in the HSC/
lymphoid progenitor stain. Anti-CD34 (RAM34) and CD16/32 (2.4G2; BD
Pharmingen) antibodies conjugated to FITC and PE, respectively, were
included in the myeloid progenitor stain.
Histology
Tissue samples were ﬁxed in 10% phosphate-buffered formalin solution
and labeled without experimental details. Slides were embedded in parafﬁn,
sectioned, and stained by the UAB Animal Resources Program Comparative
Pathology Laboratory, and then read by a pathologist (T. Schoeb) blinded to
experimental details. Tissues were scored according to the extent of disease
and the severity of disease, and the product of these scores was reported.
Laboratory Analysis
Complete blood counts were performed on heparinized whole blood
samples obtained by tail bleeding, and analysis was performed by the UAB
Animal Resources Program Comparative Pathology Laboratory using Abaxis
VetScan HMII7 (Abaxis VetScan, Union City, CA).
Statistical Analysis
Statistical signiﬁcance was determined using either unpaired or paired
Student t-test, as indicated in text. P values are reported in text. Survival
analysis was performed using the Cox-Mantel test.
RESULTS
GVHD Induced by Naïve CD4þ cells is Associated with BM
and Spleen Hypocellularity and Th1 Cell Predominance
GVHD occurs in the setting of allo-disparity between
hematopoietic stem cell donor and recipient, and can be
mediated by both CD4þ and CD8þ T cells. To investigate
effector CD4þ T cell development in the setting of GVHD and
BM failure, we used the MHC class II-disparate C57BL/6 (B6)
to B6.C-H-2bm12 (bm12) model, in which GVHD is mediated
solely by CD4þ T cells [22,23].
Bm12 recipients of allogeneic naïve B6 CD4þ T cells
succumb to GVHD within 3 weeks of transfer of 105 or 106
cells (Figure 1A). BALB/c recipients of naïve B6 CD4þ T cells
(complete MHC mismatch) develop GVHD with a similar
time course (Figure 1B). In the absence of GVHD, irradiated
murine recipients of BM alone are usually well engrafted
within 3 weeks of transplantation (not shown). Irradiated
CD45.2 bm12 recipients of 104 allogeneic CD4þCD25-CD45.1
T cells were monitored for at least 6 weeks
posttransplantation. Death from GVHD generally occurred
between weeks 2 to 4 posttransplantation for those mice
experiencing severe disease (Figure 1A). To ensure adequate
time for engraftment of donor BM cells, mice dying after 3
weeks were selected for histological evaluation. GVHD target
organs (lung, skin, liver, and gastrointestinal tract) were
evaluated histologically, as were hematopoietic sites (BM
and spleen). In addition to disease in typical GVHD target
organs, the BM and spleen demonstrated loss of normal
architecture and moderate to severe aplasia, whereas those
tissues from the negative control groups had absent or mild
disease (Figure 1C).
Donor T cells recovered from spleen and lymph nodes of
bm12 recipients were distinguished by the CD45.1/45.2
allotype and phenotyped by ﬂow cytometry. In agreement
with previous studies [24-26], the majority of donor CD4þ T
cells produced IFNg, consistent with a Th1 allo-response
(Figure 2A, B). TNFa levels were slightly decreased in donor
CD4þ T cells (Figure 2C). There was no signiﬁcant increase in
IL-17, IL-4, or IL-13 in donor CD4þ T cells (Figure 2A, not
shown) suggesting that the IFNg-positive T cells in the BM
developed via the Th1 pathway. Studies performed using
BALB/c recipients gave similar results (Figures 1B, 2A).
Because of the presence of severe BM disease in alloge-
neic recipients of naïve CD4þ T cells (Figure 1C), we isolated
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Figure 1. Naïve CD4þ T cell transfer induces lethal graft-versus-host disease,
including severe bone marrow aplasia. Wild-type C57BL/6 (B6) naïve CD4þ
cells were puriﬁed and transferred to lethally irradiated allogeneic B6.C-H-
2bm12 (bm12) at varying doses, along with T cell-depleted bone marrow
(TCD BM). Negative controls were syngeneic B6 recipients (syngeneic control)
or bm12 recipients of TCD BM. Kaplan-Meier survival curves are shown in (A)
for these experiments, with the number of mice in each group indicated in
legend. (B) Shows Kaplan-Meier curves for similar experiments using alloge-
neic BALB/c (H-2d) and syngeneic B6 recipients of 1  106 naïve B6 (H-2b)
CD4þ cells, with TCD BM. Moribund mice from (A) were sacriﬁced (along with
negative control mice) and tissues sent for histology scoring (extent multiplied
by severity) by an independent pathologist blinded to experimental details.
Shown in (C) are the scoring results from these tissues. Error bar indicates
SEM. Results are from 5 independent experiments.
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syngeneic control recipients, donor CD45.1 T cells were
present at 2- to 3-fold increased numbers in allogeneic BM
(not shown). Intracellular cytokine staining revealed
markedly increased IFNg in donor CD4þ cells from alloge-
neic compared to syngeneic recipients (Figure 2D, E), indi-
cating a predominance of donor Th1 cells within the
affected BM.
In Vivo-generated IFNg-reporter-positive Th1 Cells
Demonstrate Marked Alloreactivity and Expansion in the
Allogeneic Host
To assess the stability and pathogenic potential of allo-
geneic Th1 cells, we performed transfer experiments using
puriﬁed Th1 cells. To avoid the possibility that Th1 cells
derived ex vivo might not accurately recapitulate all func-
tional features of Th1 cells normally developing in GVHD, we
designed a unique model likely to more closely replicate
human clinical HSCT. To this end, we utilized transgenic
IFNg-reporter (Ifng/Thy1.1 BAC-In) mice, describedpreviously [8]. In this model, the thy1.1 reporter is under
control of an Ifng BAC transgene such that Ifng expression is
reported without perturbing endogenous Ifng alleles. Use of
these reporter mice enables isolation of T cells that have
undergone Ifng transcription by stably marking them with
surface Thy1.1 expression. This provides ameans for isolating
naturally arising Th1 cells directly ex vivo without require-
ment for stimulation. Because Thy1.1 is not expressed in
either B6 or bm12 mice, IFNg-competent (Thy1.1þ) T cells
could be isolated by magnetic sorting.
Alloreactive IFNg-positive Th1 cells were generated
in vivo by transplanting naïve Ifng/Thy1.1 BAC-In CD45.2
CD4þ Tcells into irradiated bm12mice (termed donor bm12).
Six days after transfer, spleens were harvested from these
mice and Thy1.1-positive CD4þ T cells were isolated
(Supplemental Figure 1). Thy1.1 purity was 95 in all
experiments, and Th1 commitment was conﬁrmed in the
Thy1.1 population by demonstrating T-bet positivity by ﬂow
cytometry (Supplemental Figure 1). Intracellular cytokine
staining of Thy1.1-positive cells demonstrated low levels of
the lineage-associated cytokines for Th2 (IL-4), Th9 (IL-9),
Th17 (IL-17), and Th22 (IL-22) T cells (Supplemental
Figure 1). To test the functional capacity of isolated Th1
cells, 1  106 Thy1.1þ cells were transferred into lethally
irradiated bm12 (recipient bm12) or syngeneic B6 mice,
along with CD45.1, T cell-depleted BM (2  106 cells per
mouse). Ten days after transplantation, spleens from recip-
ient mice were harvested and analyzed by ﬂow cytometry
(Figure 3A-C).
We recovered increased numbers of transferred in vivo-
generated Th1 cells from allogeneic recipients compared to
syngeneic controls (Figure 3D). These studies demonstrated
that naturally arising Th1 cells retain this phenotype while
undergoing marked expansion in the allogeneic host. Studies
of allogeneic Th1 cells isolated from BALB/c mice trans-
planted with naïve CD4þ T cells from Ifng/Thy1.1 BAC-In mice
and then transferred into a second cohort of BALB/c recipi-
ents showed similar results (not shown). Similar results were
also obtained using Th1 cells generated in vitro from poly-
clonal wild-type B6 CD4þ cells or antigen-speciﬁc CD4þ T
cells from 3BBM74 transgenic TCR mice (Supplemental
Figure 2). The 3BBM74 TCR T cells are speciﬁc for the MHC
class I-A bm12 mutation and are known to induce GVHD in
bm12 recipients [27,28]. These studies demonstrate that Th1
cells given at high doses are capable of lethality, even with
a polyclonal TCR population.
Allogeneic Th1 Cells Induce BM and Spleen Aplasia in
a Dose-dependent Manner
To assess GVHD manifestations induced by naturally
arising allogeneic Th1 cells, we transplanted puriﬁed Thy1.1þ
cells at de-escalating doses into lethally irradiated recipient
bm12 mice and syngeneic B6 controls, along with T cell-
depleted BM (Figure 4A). Survival curves revealed that
a low dose of alloreactive Thy1.1þ T cells (1  103) was
capable of inducing lethal disease in one-half of the bm12
recipients. Lethal disease in low dose recipients of Thy1.1þ
cells was overcome, however, by increasing the cell dose of
concomitantly administered TCD BM (Supplemental
Figure 3).
Tissues of recipient mice were assessed to identify the
mechanism of lethality. Histopathology revealed the absence
of disease in typical GVHD target organs (skin, liver, lung, and
small and large intestines) (Figure 4B). Stomach, pancreas,
thymus, and the central nervous systemwere also unaffected
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Figure 2. Th1 effector cells are present within allogeneic lymphoid tissues and bone marrow (BM) in the setting of graft-versus-host disease. Naïve CD45.1þCD4þ T
cells (1  106) from C57BL/6 (B6) donors were transferred, along with T cell-depleted CD45.2þ B6 BM, to lethally irradiated B6.C-H-2bm12 (bm12), BALB/c, or B6
recipients. Six days later, recipient mice were sacriﬁced and intracellular cytokine or FoxP3 staining and ﬂow cytometric analysis was performed on lymphocytes
collected from peripheral lymph nodes (LN), mesenteric lymph nodes (mLN), and spleen. (A) Shows representative data for transferred and BM-derived CD4þ cells
recovered from peripheral LN of syngeneic B6 control (left) and allogeneic bm12 (middle), and BALB/c (right) recipient mice. Cells were gated by lymphocyte gate,
followed by live cells (live/dead staining), and CD4 and CD45.1-positive cells. (B) Shows pooled results for IFNg staining for donor CD4þ cells (CD45.1þ) isolated from
LN, mLN, and spleen of B6 and bm12 recipients. Columns indicate mean value with individual percentages displayed by circles. Error bars indicate SEM. Percentage of
donor CD4þ TNF-a positivity is displayed in (C) from the same tissues of B6 and bm12 recipients. Columns indicate mean value and error bars indicate SEM. Bone
marrow was harvested from allogeneic and syngeneic control recipients and ﬂow cytometric analysis performed. Cells were gated by lymphocyte gate, followed by
live cells (live/dead staining) and CD4-positive cells. Donor T cells were identiﬁed by CD45.1-staining. Representative IFNg staining from a bm12 (allogeneic) recipient
is shown in (D). Pooled IFNg staining results from recipient BM are shown in (E). IFNg-positive staining was signiﬁcantly increased in donor T cells from allogeneic
recipients compared to syngeneic recipients (P ¼ .001). Error bars indicate SEM. Results are derived from 5 separate experiments.
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disease (Figure 4B). Speciﬁcally, recipients of allogeneic
CD4þThy1.1þ T cells demonstrated absence of normal splenic
architecture compared to negative controls (Figure 4C, D).Both red and white pulp areas were severely disrupted, with
thewhite pulp demonstrating more severe cellular depletion
(Figure 4D). Peripheral blood CBC data revealed increased
suppression of white blood cells, compared with other
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Figure 3. Th1 cells expand and retain Th1 phenotype in allogeneic but not syngeneic hosts. Puriﬁed Ifng/Thy1.1 BAC-In CD45.2þ Thy1.1-positive cells (1  106) were
transferred to lethally irradiated allogeneic bm12 or syngeneic B6 control recipients, along with CD45.1þ TCD BM (2  106). Ten days later, spleens were harvested
from recipient mice and analyzed by ﬂow cytometry. Shown in (A) are representative FACS analyses of Thy1.1 expression on live-gated CD45.2þ cells recovered from
spleens of bm12 (allogeneic) and B6 (syngeneic) recipients. Shown in (B) and (C) are the cumulative results for Thy1.1 and IFNg staining, respectively, from donor
CD4þ cells recovered from recipient splenic tissue. Recovered Thy1.1þ cell numbers are shown in (D). Results are representative of 3 independent experiments.
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from recipients of allogeneic CD4þThy1.1þ T cells demon-
strated severe aplasia (Figure 4E, F). Notably, ﬂow cytometric
analysis of BM revealed a marked decrease in donor hema-
topoietic chimerism in recipients of Thy1.1þ cells
(Supplemental Figure 4B, C).
Allogeneic Th1 Cells Demonstrate Increased Toxicity to
the Lymphoid Compartment, Including BM Lymphoid
Progenitors
Histology and peripheral blood counts indicated that
allogeneic Th1 cells induce increased toxicity to the
lymphoid compartment in allogeneic recipients (Figure 4D
and Supplemental Figure 4A). Flow cytometric analyses of
recipient BM and spleen were performed to further assess
the presence of a lineage-speciﬁc suppression by allogeneic
Th1 cells. Total cell counts were reduced by 50% to 90% in
recipients of allogeneic CD4þThy1.1þ T cells compared with
syngeneic CD4þThy1.1þ control recipients and allogeneicrecipients of BM only. Myeloid and lymphoid total cell
numbers were both reduced, but lymphoid cells were more
severely affected (Supplemental Figure 5). There were
decreased percentages of B cells (by CD19 and B220 staining),
CD8þ cells, and BTLA-expressing B and T lymphocytes.
Natural killer cell percentages between allogeneic and
syngeneic recipients were not signiﬁcantly different.
Although the absolute number of myeloid cells was also
reduced, there was an increased percentage of CD11c-
expressing cells and CD11bþGr-1þ neutrophils in allogeneic
recipients (Supplemental Figure 5).
Additional analyses were performed to examine the effect
of allogeneic CD4þThy1.1þ cells on recipient hematopoietic
stem cell progenitor populations. Bone marrow harvested
from recipients of allogeneic CD4þThy1.1þ T cells and nega-
tive controls 4 weeks after transplantation was analyzed by
ﬂow cytometry. Recipients of allogeneic CD4þThy1.1þ cells
demonstrated reduced percentages and absolute numbers of
c-KitþSca-1þlineage marker-, IL7Raþ common lymphoid
Figure 4. Allogeneic Th1 cells mediate spleen and bone marrow aplasia. Puriﬁed Ifng/Thy1.1 BAC-In CD4þThy1.1þ cells were harvested from donor bm12 mice and
transferred to lethally irradiated syngeneic B6 and allogeneic recipient bm12 mice. Kaplan-Meier survival curves for different doses of transferred cells are displayed
in (A). The number of mice included in each curve is shown in the legend. Allogeneic mice succumbing to disease were sacriﬁced and histologic scoring performed by
an independent, blinded pathologist. Scores for indicated tissues are shown in (B). Results are cumulative from 5 independent experiments. (C) Shows representative
images of splenic tissue from syngeneic (left) and allogeneic (right) recipients. Images are at 10 times magniﬁcation. Cumulative histologic scoring results for white
pulp (WP) and red pulp (RP) from syngeneic and allogeneic recipients are shown in (D). P value indicates paired Student t-test analysis for allogeneic red pulp
compared to allogeneic white pulp. Representative images (10 times magniﬁcation) and histologic scoring results for bone marrow tissues are shown in (E) and (F),
respectively. Cumulative tissue scores were obtained by multiplying extent and severity (see Methods). Error bars indicate SEM.
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(Figure 5A). No differences were seen in percentages
of common myeloid progenitor cells (c-KitþSca-1
CD34þCD16/32), megakaryocyte-erythroid progenitor cells
(c-KitþSca-1 CD34CD16/32), and granulocyte-
macrophage progenitor cells (c-KitþSca-1 CD34þCD16/
32þ); however, total numbers of all populations were
signiﬁcantly decreased in recipients of allogeneic
CD4þThy1.1þ cells compared with controls (Figure 5B, D).
Finally, an increased percentage of c-KitþSca-1þlineage
marker hematopoietic stem cells was noted in allogeneic
Thy1.1þ cell recipients compared to controls, but total
numbers of these cells were similar in both groups
(Figure 5C, D). Collectively, these results indicate global
suppression of recipient hematopoietic lineages with
a greater effect on committed lymphoid populations.Th1 Cells Express the Chemokine Receptor CXCR4 and
Demonstrate Preferential Homing to BM and Spleen in
Allogeneic Recipients
The induction of BM and spleen aplasia by transferred Th1
cells in the absence of disease in typical GVHD target tissues
suggested tissue-speciﬁc homing of these cells. To assess
this, the surface expression pattern of homing receptors on
CD4þThy1.1þ T cells isolated from spleen and peripheral
lymph nodes of recipients of allogeneic Th1 cells was
analyzed using splenic CD4þ cells from nonirradiated bm12
mice as controls. Most spleen-derived CD4þ cells had
a CD44hiCD62Llo phenotype, consistent with previous acti-
vation (Figure 6A). Speciﬁc analysis of Thy1.1þ Th1 cells
revealed a similar pattern, with a slightly increased
frequency of CD62Lhi expression in lymph nodes. CCR7
expression was low to absent on Thy1.1þ cells [30].
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Figure 5. Allogeneic Thy1.1 cells demonstrate toxicity to common lymphoid progenitors. Puriﬁed Ifng/Thy1.1 BAC-In CD4þThy1.1þ cells (CD45.2þ) were transferred to
lethally irradiated B6.C-H-2bm12 (bm12) mice at a dose of 1  105 cells per mouse, along with 3  106 TCD bone marrow (BM) cells (BM þ Th1). Control bm12 mice
were given only TCD BM cells (BM only). Fourweeks later, all micewere sacriﬁced, BM removed from both tibias and femurs, and cell counts performed. Cells were then
analyzed by ﬂow cytometry to analyze BM progenitors. The ﬂow cytometric gating procedure is detailed in Materials and Methods. Frequency of common lymphoid
progenitors is shown in (A). Shown in (B) are the frequencies of myeloid progenitor populations: common myeloid progenitor (CMP) cells, granulocyte-macrophage
progenitor (GMP) cells, and megakaryocyte-erythroid progenitor (MEP) cells. The frequencies of hematopoietic stem cells (HSCs) in the experimental and control
groups are shown in (C). Total BM cell numbers obtained from recipients of BM only and BMþ Th1 cells are shown in (D). Analysis performed using an unpaired Student
t-test demonstrated a statistically signiﬁcant difference ( P ¼ .002). Data represent cumulative results from 5 mice per group. Error bars indicate SEM.
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all Thy1.1þ Tcells were T-betþFoxp3-, consistent with a stable
Th1 effector-memory phenotype (Figure 6B) [31].
Additional staining was performed to assess expression of
chemokine receptors. Notably, Thy1.1þ cells obtained from
the spleen expressed very high levels of CXCR4 (Figure 6C),
a receptor known to be responsible for CD4þ cell homing to
BM and spleen [32,33]. Additionally, these cells lacked
receptors known to facilitate homing to the GI tract, specif-
ically CCR6 and CCR9 (Figure 6C) [34,35]. Thy1.1þ cells also
expressed high levels of CCR5 and CXCR3, receptors associ-
ated with Th1 cells [36,37].
Homing experiments were performed to determine
whether Thy1.1þ cells isolated from spleen preferentially
migrated to the BM and spleen after transfer to recipient
bm12 mice. Thy1.1þ T cells were puriﬁed and transferred to
lethally irradiated bm12 and syngeneic B6 mice. Two weeks
later, tissues were harvested and analyzed for presence of
donor T cells. As shown in Figure 6D, donor T cells were
identiﬁed within recipient BM and spleen. Insufﬁcient cells
were obtained from gastrointestinal tissues for analysis, but
analysis of mesenteric lymph nodes revealed no donor
CD4þThy1.1þ cells (Figure 6D). Donor CD4þ cells were also
identiﬁed within lung tissue of recipient mice (Figure 6D),
consistent with known CXCL12 expression [38]. Thy1.1
expression analysis revealed that these donor CD4þ cells
maintained a Th1 phenotypewithin these tissues (Figure 6E).Allogeneic Th1 Cells are Activated by Radiation-resistant
Recipient BM and Spleen Cells and Induce Aplasia
Through an IFNg-dependent Mechanism
Similar tomyeloablative HSCT in humans, in these studies
donor BM and Th1 cells are from the same MHC background.
In the setting of lethal irradiation, however, radiation-
resistant hematopoietic and nonhematopoietic recipient
cells persist within BM and other tissues [39,40], suggesting
that donor Th1 cells might generate an allo-response against
these remaining recipient BM and spleen cells.
Initial in vitro studies determined whether radio-
resistant cells within recipient BM were capable of stimu-
lating Thy1.1þ donor T cells. B6 (control) and bm12 mice
were administered lethal doses of irradiation and 6 days later
(before death) BM cells were removed and placed into
culture with puriﬁed CD4þThy1.1þ T cells. Flow cytometric
analysis performed 48 hours later demonstrated that the
CD4þThy1.1þ cells retained IFNg expression (as measured by
Thy1.1 staining) and secreted increased levels of IFNg (by
ELISA) when stimulated with allogeneic radio-resistant BM
cells to levels comparable to the positive control (Figure 7A
and not shown). Furthermore, Thy1.1þ cells also underwent
proliferation after coculture with allogeneic bm12 BM cells,
compared to control BM cells, as measured by carboxy-
ﬂuorescein succinimidyl ester-staining (not shown).
To conﬁrm these ﬁndings in vivo, the same trans-
plantation schema described previously was used except
0 102 103 104 105
0
100
200
300
400
4.12
0 102 103 104 105
0
200
400
600
6.52
0 102 103 104 105
0
100
200
300
400
500
0.0403
0 102 103 104 105
0
10
20
30
40
7.06
CD4 
Bone Marrow Spleen Mesenteric LN Lung 
Co
ntr
ol
All
og
en
eic
 Sp
lee
n
All
og
en
eic
 LN
Sp
lee
n T
hy1
.1 
po
siti
ve
LN
 Th
y1
.1 
po
siti
ve
0
20
40
60
80
100
CD62Lpos CD44low
CD62Lpos CD44high
CD62Lneg CD44high
Cell Source
FA
CS
 
po
sit
ive
 
(%
)
C
o
n
tr
o
l
T
h
y
1
.1
 p
o
s
it
iv
e
0
20
40
60
80
100
C
C
R
6
 p
o
s
it
iv
e
(
%
)
C
o
n
tr
o
l
T
h
y
1
.1
 p
o
s
it
iv
e
0
20
40
60
80
100
C
C
R
5
 p
o
s
it
iv
e
(
%
)
C
o
n
tr
o
l
T
h
y
1
.1
 p
o
s
it
iv
e
0
20
40
60
80
100
F
o
x
P
3
 p
o
s
it
iv
e
(
%
)
C
o
n
tr
o
l
T
h
y
1
.1
 p
o
s
it
iv
e
0
20
40
60
80
100
T
b
e
t
 P
o
s
it
iv
e
 
(
%
)
C
o
n
tr
o
l 
T
h
y
1
.1
 p
o
s
it
iv
e
 
0
20
40
60
80
100
C
X
C
R
4
 p
o
s
it
iv
e
(
%
)
C
o
n
tr
o
l
T
h
y
1
.1
 p
o
s
it
iv
e
0
20
40
60
80
100
C
C
R
9
 P
o
s
it
iv
e
(
%
)
B
o
n
e
 M
a
r
r
o
w
S
p
le
e
n
M
e
s
 L
N
L
u
n
g
0
20
40
60
Allogeneic Target Tissue
T
h
y
1
.1
 p
o
s
it
iv
e
 c
e
ll
s
(
%
)
Figure 6. Allogeneic Thy1.1 cells home to bone marrow (BM) and spleen. Puriﬁed Thy1.1-positive Ifng/Thy1.1 BAC-In CD45.2þCD4þ cells were harvested from allo-
geneic donor bm12 mice. Staining was performed for CD62L and CD44, and cumulative ﬂow cytometry results are shown in (A). Cells were gated ﬁrst by lymphocyte
gate, followed by live cells (live/dead staining) and CD4- and CD45.2-positive cells. Control cells were obtained from spleens of nonirradiated bm12 mice. Analysis
performed on CD4-positive cells within spleen and lymph node (LN) is labeled allogeneic spleen and allogeneic LN, respectively. Analysis performed on Thy1.1-
positive cells is labeled spleen Thy1.1 positive and LN Thy1.1 positive, respectively. Error bars indicate SEM. Intracellular FACS staining for T-bet and FoxP3 was
performed on Thy1.1 positive cells harvested from spleen and LN, and cumulative results are shown in (B). Cumulative staining results for selected chemokine
receptors are shown in (C). These results are from 2 independent experiments using 10 mice. Puriﬁed Ifng/Thy1.1 BAC-In CD4þThy1.1þ cells (CD45.2þ) were harvested
from donor bm12 mice and transferred to lethally irradiated syngeneic B6 and allogeneic recipient bm12 mice, along with CD45.1þ TCD BM. Two weeks later, mice
were sacriﬁced and tissues analyzed for the presence of donor Thy1.1þ cells. Shown in (D) are representative CD4þ histograms from various labeled tissue sites. Cells
were gated by lymphocyte gate, followed by live cells (live/dead staining) and CD45.2-positive cells. The cumulative percentage of Thy1.1-expressing CD4þ cells
within these tissues is shown in (E). Results are from 2 independent experiments.
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Figure 7. Allogeneic Th1 cells are activated by radiation-resistant recipient bone marrow (BM) cells and mediate BM failure through an IFNg-dependent mechanism.
B6 (syngeneic) and bm12 (allogeneic) mice were administered lethal irradiation and BM harvested from tibias and femurs 6 days later, before death. RBCs were lysed
and recovered BM cells were added to culture. Puriﬁed CD4þThy1.1þ cells from donor bm12 mice were labeled with CFSE and added to bm12 (bm12 BM) or B6 BM
cells. Positive control (labeled “Control”) included puriﬁed Thy1.1-positive cells co-cultured with B6 (syngeneic) BM cells along with anti-CD3 antibody stimulation.
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controls. Mice were sacriﬁced 4 weeks later, and BM was isolated from femurs and tibias. Fluorescence activated cell staining was performed, and representative
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Shown in (E) are Kaplan-Meier survival curves. Statistical analysis revealed a signiﬁcant difference in survival in recipients of wild type BM (P ¼ .01). Analysis of IFNgR
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J.H. Chewning et al. / Biol Blood Marrow Transplant 19 (2013) 876e887884that BALB/c rather than bm12micewere used as recipients to
enable discrimination of donor and recipient cell pop-
ulations. Using this experimental design, BALB/c cells
remaining in the BM after irradiation were identiﬁed based
on their expression of H-2d. Puriﬁed B6 CD4þThy1.1þ cells
(0.5  105 to 1  105 cells per mouse) underwent trans-
plantation into lethally irradiated BALB/c mice along with T
cell-depleted B6 BM cells. BALB/c recipients of BM only andbm12 recipients (H-2b) of B6 BM were used as controls. All
mice were sacriﬁced after 4 weeks, and BM was isolated. BM
cellularity was markedly reduced in recipients of allogeneic
Thy1.1þ Th1 cells compared to BM only recipients (not
shown). Furthermore, analysis of H-2d expression revealed
reduced numbers of BALB/c-derived H-2d expressing cells
within the marrow of Th1 cell recipients compared to
recipients of BM only (Figure 7B, C). Recipients of Th1 cells
J.H. Chewning et al. / Biol Blood Marrow Transplant 19 (2013) 876e887 885demonstrated reduced BM cell numbers and loss of cells of
recipient origin (BALB/c) within the BM, indicating that the
transferred Thy1.1þ cells likely recognize remaining radio-
resistant recipient cells.
Th1 cells can mediate cytotoxic allogeneic effects through
several mechanisms, including IFNg secretion and Fas-FasL
interactions. To determine whether either mechanism
might be responsible for the BM and spleen aplasia induced
by alloreactive Th1 cells, B6 CD4þThy1.1þ cells (0.5105 cells
per mouse) underwent transplantation into bm12 recipients
along with TCD BM cells from IFNg receptor (IFNgR)-deﬁ-
cient, Fas-deﬁcient, or WT mice (all B6 background). Recip-
ients of IFNgR-deﬁcient BM demonstrated signiﬁcantly
reduced histologic scoring compared to WT controls
(Figure 7D). Recipients of Fas-deﬁcient BM had reduced
disease that did not achieve statistical signiﬁcance, despite
increased expression of CD178 (Fas ligand) by the Thy1.1þ
Th1 cells (not shown). Recipients of IFNgR-deﬁcient and Fas-
deﬁcient demonstrated improved survival compared to
recipients of WT BM (P ¼ not signiﬁcant by Cox-Mantel test)
(Figure 7E). Collectively, these data indicate that allograft Th1
cells recognize radiation-resistant cells in the recipient BM
that induce the release of IFNg, which is directly toxic to
donor hematopoietic cells.
DISCUSSION
The studies herein utilize a novel reporter mouse system
to determine the alloresponse of highly puriﬁed Th1 cells in
several distinct mouse models of GVHD. Our studies have
extended previous work by deﬁnitively demonstrating that
Th1 cells directly mediate BM failure in allogeneic host mice.
Furthermore, we have signiﬁcantly advanced these ﬁndings
to demonstrate that allogeneic Th1 cells home preferentially
to spleen and marrow, and induce a marked suppression of
the lymphoid compartment, including common lymphoid
progenitors. Our results provide preliminary evidence indi-
cating that allogeneic Th1 cells recognize radiation-resistant
host cells remaining within host BM, inducing activation and
IFNg release. Finally, we have shown that Th1-mediated BM
suppression occurs through an IFNg-dependent mechanism.
Our ﬁndings demonstrate that alloreactive Th1 cells that
develop during GVHD are capable of inducing lethal BM
failure in fully myeloablated MHC-disparate recipients, and
that graft failure is mediated through an IFNg-dependent
mechanism. This is the ﬁrst study to directly demonstrate
a Th1 cell-mediated allo-response in BM and was enabled by
implementation of IFNg-reporter mice that allows isolation
of differentiated Th1 cells without requirement for T cell
stimulation, which can induce Th1 cell apoptosis. This model
has the further advantage that it utilizes effector T cells that
develop in the context of a natural allo-response in vivo,
thereby recapitulating the normal expression of chemokine
and other receptors present in transplanted cellular grafts
and more closely mimicking the human transplantation
setting.
A role for IFNg in mediating BM and spleen aplasia in
sublethal models of HSCT was previously reported [12,13];
however, it appeared to play a protective role in the setting of
ablative conditioning [13]. Our studies have focused on the
myeloablative HSCT setting, where recipient hematopoiesis
is eliminated. Studies using lethally irradiated recipients
demonstrated a role for CD8þ and CD4þ cells in mediating
BM aplasia [18,20]. In these studies, CD4þ Tcell-mediated BM
aplasia occurred primarily through Fas-FasL interactions and
B cells were primarily affected [20]. Fas-FasL interactionshave also been shown to be important in mouse models of
aplastic anemia [41]. Our studies differ from the aforemen-
tioned studies because we have utilized adoptive transfer
methodologies to determine a direct role for puriﬁed,
committed Th1 cells in mediating BM failure. These experi-
ments revealed that CD4þ cells are capable of inducing
severe BM failure that is primarily mediated through IFNg.
Our studies indicate that allogeneic Th1 cells are activated
by radiation-resistant hematopoietic or nonhematopoietic
BM cells. Recent studies have shown that GVHD can be
mediated by recipient nonhematopoietic antigen-presenting
cells (APC), and that these cells appear even more potent in
generating GVHD than donor-derived hematopoietic APCs
[42,43]. Our studies have demonstrated that these radiation-
resistant APCs were sufﬁcient for activation of allogeneic Th1
cells in the allograft, resulting in IFNg-induced toxicity that
targeted BM hematopoietic cells through a mechanism yet to
be deﬁned (Figure 7). Although a minor role for Fas-
dependent cytotoxicity could not be excluded based on
survival curves (Figure 7E), histologic analysis demonstrated
that BM toxicity mediated by IFNg was clearly dominant
(Figure 7D). It is possible, however, that IFNg and Fas-FasL
interactions are not mutually exclusive, and future studies
will address possible mechanisms of IFNg-mediated aplasia.
A profound suppressive effect was noted on lymphoid,
myeloid, and erythroid lineages within the peripheral blood
and BM by allogeneic Th1 cells (Supplemental Figures 4A, 5).
More severe damage to splenic white pulp was also consis-
tent with peripheral lymphocyte destruction (Figure 4D).
These ﬁndings are in agreement with previous studies
[11,16]. Flow cytometry data revealed a lesser effect on
myeloid populations, with increased percentages of CD11c-
and Gr-1-positive cells within recipient BM likely indicating
the preferential targeting of lymphoid lineages
(Supplemental Figure 5). Our studies also revealed decreased
hematopoietic progenitors from all lineages within the
allogeneic host BM, with a more pronounced effect seen on
common lymphoid progenitors (Figure 5). Collectively, these
studies indicate that allogeneic Th1 cells induce BM failure,
with a greater suppressive effect on the lymphoid lineage
(both committed lymphocytes and common lymphoid
progenitor cells), perhaps secondary to differential IFNg
receptor expression [44,45]. Future studies will explore the
mechanism of this lymphoid “bias” by allogeneic Th1 cells.
Thy1.1þ cells within the BM and spleen of allogeneic
recipients expressed high levels of the chemokine receptor
CXCR4. This receptor has previously been shown to be critical
for CD4þ T cell trafﬁcking between BM and peripheral blood
[32]. In addition to homing, CXCR4 also has a role in T cell
signaling and upregulation of antiapoptotic proteins [46,47].
We have demonstrated that murine naïve CD4þ Tcells grown
in vitro in Th1 conditions also upregulate CXCR4 (unpub-
lished data). These studies demonstrate that transferred
Thy1.1þ effector Th1 cells accumulate within allogeneic BM
associated with increased CXCR4 expression. Further studies
are required to determine if CXCR4 expression is required for
Th1-induced BM failure.
IFNg has also been shown to be critical in mediating
gastrointestinal GVHD [48,49]. We found Th1 cells present in
gastrointestinal tissues after allogeneic naïve CD4þ trans-
plantation, consistent with previous studies [25,48,49].
However, we did not ﬁnd disease in these organs after
puriﬁed Thy1.1þ cell transfer, nor was there any evidence of
homing to the gastrointestinal tract by the Th1 cells used
herein. This is likely due to the absence of important gut-
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transferred effector Th1 cells [34,35], and likely reﬂects the
fact that the Thy1.1þ T cells used were harvested from donor
spleens. Despite expressing the chemokine receptors CXCR3
and CCR5, wewere unable to detect pathology within skin or
liver of recipient mice. It is currently not knownwhether this
is secondary to absence of trafﬁcking to these tissues or
whether committed Th1 cells do not induce disease in these
tissues [25]. Interestingly, transferred allogeneic Th1 cells
were recovered from the lungs of recipient mice (Figure 6D),
but there was no signiﬁcant pathology in this tissue. This is
consistent with previous reports that IFNg is not an impor-
tant mediator of lung GVHD [48,50]. It is possible that Th1-
mediated disease occurs within the BM because the
marrow is simply a more sensitive organ to allogeneic T cell
effects compared with other end-organs. However, we feel it
is less likely as the disease pattern in recipient mice tissues
was similar, even at higher doses of allogeneic Th1 cells
(Figure 4).
The current studies were designed to mimic human stem
cell transplantation. For this reason, Thy1.1þ cells were
generated in vivo and acquired from only the spleens (and
not lymph nodes) of donor mice because these cells reﬂect
peripheral blood composition that is consistent with the
clinical scenario in human HSCT using peripheral blood or
BM harvested cells [51-53]. In contrast to the clinical setting,
however, we did not utilize cytokine-mobilized or condi-
tioned BM for these studies. These studies also used rela-
tively lower doses of transferred CD4þ T cells and BM
compared with other models [13,24]. Future studies will
address whether cytokinemobilization of donor BM can alter
the suppressive effect of Th1 cells and/or IFNg.
In summary,wehave here conclusively demonstrated that
allogeneic Th1 cells induce secondary BM failure through
IFNg-mediated and perhaps other minor mechanisms. This
study illuminatesat leastonepossible etiology for graft failure
and poor graft function associated with human GVHD and
should impact the design of future trials for improved
hematopoietic stem cell graft manipulation in humans.
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